Induction of cardiac angiotensinogen mRNA and angiotensin converting enzyme (ACE) activity in isoproterenol-induced heart injury

Hypertension Research - Clinical and Experimental

Volumn 19, Issue 3, 1996, Pages 179-187

  Ogiku, Noriko ^a   Ishida, Ryuichi ^a   Saeki, Kazuhiko ^a   Sugiura, Masaki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

ACE; Angiotensinogen; Imidapril; Isoproterenol; SHR

Indexed keywords

ANGIOTENSINOGEN; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; ISOPRENALINE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0029985136     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.19.179     Document Type: Article

References (53)

1. Thomas JA, Marks BH: Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978; 41: 233-243.
2. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH: Relation of renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.
3. Smith TW, Braunwald E, Kelly RA: The management of heart failure, in Braunwald E (ed): Heart disease, A textbook of cardiovascular medicine. 1988, 3rd ed., Philadelphia, WB Saunders, pp 486-543.
4. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ: Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978; 58: 770-776.
5. Cleland JGF, Dargie HJ, Ball SG, et al: Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones and metabolic state. Br Heart J 1985; 54: 305-312.
6. Schofield PM, Brooks NH, Lawrence GP, Testa HJ, Ward C: Which vasodilator drug in patients with chronic heart failure?: a randomized comparison of captopril and hydralazine. Br J Clin Pharmacol 1991; 31: 25-32.
7. Levine TB, Olivari MT, Garberg V, Sharkey SW, Cohn JN: Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation 1984; 69: 548-553.
8. Pfeffer MA, Braunwald E, Moyé LA, et. al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
9. Studer R, Reinecke H, Müller B, Holts J, Just H, Drexler H: Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994; 94: 301-310.
10. Ciba K, Moriyama S, Ishigai Y, Fukuzawa A, Irie K, Shibano T: Lack of correlation of hypotensive effects with prevention of cardiac hypertrophy by perindopril after ligation of rat coronary artery. Br J Pharmacol 1994; 112: 837-842.
11. Hirsch AT, Talsness CE, Smith AD, Schunkert H, Ingelfinger JR, Dzau VJ: Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992; 86: 1566-1574.
12. Cebelin MS, Hirsh CS: Human stress cardiomyopathy. Hum Pathol 1980; 11: 123-132.
13. Haft JI: Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 1974; 17: 73-86.
14. Milei J, Núñez RG, Rapaport M: Pathogenesis of isoproterenol-induced myocardial lesions: its relation to human 'coagulative myocytolysis'. Cardiology 1978; 63: 139-151.
15. Beznak M: Hemodynamics during the acute phase of myocardial damage caused by isoproterenol. Can J Biochem Physiol 1962; 40: 25-30.
16. Teerlink JR, Pfeffer JM, Pfeffer MA: Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994; 75: 105-113.
17. Csapó Z, Dusek J, Rona G: Early alterations of the cardiac muscle cells in isoproterenol-induced necrosis. Arch Pathol 1972; 93: 356-365.
18. Godfraind T, Ghysel-Burton J, Sturbois X: Ionic changes evoked by isoprenaline in rat hearts in vivo and in vitro and their reduction by creatinol O-phosphate. Arzneimittelforshung 1979; 29: 1468-1470.
19. Nirdlinger EL, Bramante PO: Subcellular myocardial ionic shifts and mitochondrial alterations in the course of isoproterenol-induced cardiopathy of the rat. J Mol Cell Cardiol 1974; 6: 49-60.
20. Nagano M, Higaki J, Nakamura F, et al: Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension 1992; 19: 708-712.
21. Tisné-Versailles J, Constantin M, Lamar JC, Pourrias B: Cardiotoxicity of high doses of isoproterenol on cardiac haemodynamics and metabolism in SHR and WKY rats (41248). Arch Int Pharmacodyn 1985; 273: 142-154.
22. Yeager JC, Iams SG: Isoproterenol-induced cardiac failure in the spontaneously hypertensive rat (41248). Proc Soc Exp Biol Med 1981; 168: 137-142.
23. Wexler BC: Isoprenaline-induced myocardial infarction in spontaneously hypertensive rats. Cardiovasc Res 1979; 13: 450-458.
24. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE: Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 1990; 29: 10351-10356.
25. Noonan KE, Beck C, Holzmayer TA, et al: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-7164.
26. Gilliland G, Perrin S, Blanchard K, Bunn HF: Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 2725-2729.
27. Okubo H, Kageyama R, Ujihara M, Hirose T, Inayama S, Nakanishi S: Cloning and sequence analysis of cDNA for rat angiotensinogen. Proc Natl Acad Sci USA 1983; 80: 2196-2200.
28. Seiler-Tuyns A, Eldridge JD, Paterson BM: Expression and regulation of chicken actin genes introduced into mouse myogenic and nonmyogenic cells. Proc Natl Acad Sci USA 1984; 81: 2980-2984.
29. Kinoshita T, Imamura J, Nagai H, Shimotohno K: Quantification of gene expression over a wide range by the polymerase chain reaction. Anal Biochem 1992; 206: 231-235.
30. Weiss JL, Frederiksen JW, Weisfeldt ML: Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest 1976; 58: 751-760.
31. Itoh H, Kawashima K, Chibata I: Rapid microbiological assay of amino acids. Agric Biol Chem 1973; 37: 2227-2233.
32. Lindpaintner K, Jin M, Wilhelm MJ, et al: Intracardiac generation of angiotensin and its physilologic role. Circulation 1988; 77 (Suppl I): I-18-I-23.
33. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy effects on coronary resistance, contractility and relaxation. J Clin Invest 1990; 86: 1913-1920.
34. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT: Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-1195.
35. Sadoshima J, Xu Y, Slayter HS, Izumo S: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-984.
36. Salyers AK, Rozek LF, Bittner SE, Walsh GM: Simultaneous determination of ventricular function and systemic hemodynamics in the conscious rat. J Pharmacol Methods 1988; 19: 267-274.
37. Yeager JC, Whitehurst ME: Verapamil prevents isoproterenol-induced cardiac failure in the rat. Life Sci 1982; 30: 299-306.
38. Wexler BC: Pathophysiologic effects of pre-existing hypertension on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats. Atherosclerosis 1974; 19: 161-184.
39. Ohta H, Azuma J, Onishi S, Awata N, Takihara K, Kishimoto S: Protective effect of taurine against isoprenaline-induced myocardial damage. Basic Res Cardiol 1986; 81: 473-481.
40. Knufman NMJ, Van der Laarse A, Vliegen HW, Brinkman CJJ: Quantification of myocardial necrosis and cardiac hypertrophy in isoproterenol-treated rats. Res Commun Chem Pathol Pharmacol 1987; 57: 15-32.
41. Rona G, Chappel CI, Kahn DS: Experimental production of chronic cardiac aneurysm and congestive heart failure in the rat. Exp Mol Pathol 1963; 2: 40-51.
42. Meggs LG, Coupet J, Huang H, et al: Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 1993; 72: 1149-1162.
43. Nakamura F, Nagano M, Kobayashi R, et al: Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters. Am J Physiol 1994; 267: H2297-H2304.
44. Narita H, Kaburaki M, Yabana H, et al: Prolonging action of imidapril on the life-span expectancy of cardiomyopathic hamster. J Cardiovasc Pharmacol 1996; 27: 861-871.
45. Metsarinne K, Rosenlof K, Gronhagen RC, Fyhrquist F: Direct radio-immunoassay of renin substrate: effect of converting enzyme inhibition. Scand J Clin Lab Invest 1988; 48: 131-136.
46. Michel J-B: Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure. Eur Heart J 1990; 11 (Suppl D): 17-26.
47. Gohlke P, Linz W, Schölkens BA, et al: Angiotensin-converting enzyme inhibition improves cardiac function - role of bradykinin -. Hypertension 1994; 23: 411-418.
48. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990; 182: 395-396.
49. Kubo M, Kato J, Ochiai T, Ishida R: Pharmacological Studies on (4S)-1-methyl-3- {(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl) amino] propionyl} -2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: 1. ACE inhibitory and anti-hypertensive activities. Jpn J Pharmacol 1990; 53: 201-210.
50. Okamura T, Kitamura Y, Kimura T, Toda N: Comparison of selective actions of imidaprilat and enalaprilat on the response to angiotensin I and bradykinin in isolated dog blood vessels. Pharmacometrics 1993; 46: 427-436 (in Japanese).
51. Kubo M, Fjitsuka T, Ishida R: Effects of the new angiotensin-I-converting enzyme inhibitor imidapril on the responses of isolated vascular preparations to various agonists. Arzneimittelforshung 1992; 42: 446-451.
52. Hall D, Zeitler H, Rudolph W: Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 1549-1555.
53. Hartman JC: The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995; 60: 789-792.